AbbVie is expanding its presence in the gastroenterology market with the FDA approval of Skyrizi for ulcerative colitis. The company is positioning Skyrizi and Rinvoq as successors to Humira, aiming to boost sales and address the decline in Humira’s revenue. Despite economic challenges affecting other segments, AbbVie has raised its 2024 earnings forecast based on the strong performance of its immunology drugs.
AbbVie boosts profit outlook as Humira successors branch into gastroenterology market (Fierce Pharma)
0